Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study

References

• Colditz GA, Haukinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589–1593.
   PubMed Web of Science ®Google Scholar
• Sacco SM, Ward WE. Revisiting estrogen: efficacy and safety for post menopausal bone health. J Osteo. 2010;2010:1–8.
   Google Scholar
• Delmas PD. Clinical use of selective estrogen receptor modulators. Bone. 1999;25:115–118.
   PubMed Web of Science ®Google Scholar
• Sexton MJ, Gherman RB. Selective estrogen receptor modulators: the ideal estrogen replacement? Prim Care Update Ob Gyns. 2001;8:25–30.
   PubMedGoogle Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA. 1999;282:637–645.
   PubMed Web of Science ®Google Scholar
• Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice . N Engl J Med. 2003;348:618–629.
   PubMed Web of Science ®Google Scholar
• Patil PH, Belgamwar VS, Patil PR, et al. Solubility enhancement of raloxifene using inclusion complexes and cogrinding method. J Pharm (Cairo). 2013;2013:527380–527389.
   PubMedGoogle Scholar
• O’Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility-the potential impact of lipid-based formulations. Adv Drug Deliv Rev. 2008;60:617–624.
   PubMed Web of Science ®Google Scholar
• Shishu Rajan S. Kamalpreet Development of novel microemulsion-based topical formulations of acyclovir for the treatment of cutaneous herpetic infections. AAPS Pharm SciTech. 2009;10:559–565.
   PubMed Web of Science ®Google Scholar
• Thakkar H, Nangesh J, Parmar M, et al. Formulation and characterization of lipid- based drug delivery system of raloxifene - microemulsion and self-microemulsifying drug delivery system. J Pharm Bioall Sci. 2011;3:442–448.
   PubMedGoogle Scholar
• Elsheikh MA, Elnaggar YSR, Gohar EY, et al. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in-vivo appraisal. Int J Nanomedicine. 2012;7:3787–3802.
   PubMed Web of Science ®Google Scholar
• Chen H, Chang X, Weng T, et al. A study of microemulsion systems for transdermal delivery of triptolide. J Control Release. 2004;98:427–436.
   PubMed Web of Science ®Google Scholar
• Kumar B, Jain SK, Prajapati SK. Effect of penetration enhancer DMSO on in-vitro skin permeation of acyclovir transdermal microemulsion formulation. Int J Drug Del. 2011;3:83–94.
   Google Scholar
• Chouhan P, Saini TR. D-optimal design and development of microemulsion based transungual drug delivery formulation of ciclopirox olamine for treatment of onychomycosis. Indian J Pharm Sci. 2016;78:498–511.
   Web of Science ®Google Scholar
• Vyas TK, Babbar AK, Sharma RK, et al. Preliminary brain targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS Pharm SciTech. 2006;7:E1–E9.
   PubMed Web of Science ®Google Scholar
• Kawakami K, Yoshikawa T, Moroto Y, et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs. I. Prescription design. J Control Release. 2002;81:65–74.
   PubMed Web of Science ®Google Scholar
• Spiclin P, Homar M. Sodium ascorbyl phosphate in topical microemulsions. Int J Pharm. 2003;256:65–73.
   PubMed Web of Science ®Google Scholar
• Chen H, Chang X, Du D. Microemulsion-based hydrogel formulation of ibuprofen for topical delivery. Int J Pharm. 2006;315:52–58.
   PubMed Web of Science ®Google Scholar
• Brime B, Moreno M. Amphotericin B in oil in water lecithin-based microemulsions: formulation and toxicity evaluation. J Pharm Sci. 2002;91:1778–1785.
   Web of Science ®Google Scholar
• Laithy HMEl, Shaboury KMFEl. The development of cutina lipogel and gel microemulsion for topical administration of Fluconazole. AAPS Pharma SciTech. 2002;3:77–85.
   Google Scholar
• Boonme P, Krauel K, Graf A, et al. Characterization of microemulsion structures in the pseudoternary phase diagram of isopropyl palmitate/water/Brij 97:1-Butanol. AAPS Pharm SciTech. 2006;7:E99–104.
   PubMed Web of Science ®Google Scholar
• Sarciaux JM, Acar L, Sado PA. Using microemulsion formulations for oral drug delivery of therapeutic peptides. Int J Pharm. 1995;120:127–136.
   Web of Science ®Google Scholar
• Kushwaha AK, Vuddanda PR, Karunanidhi P, et al. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. Biomed Res Int. 2013;2013:1–9.
   Web of Science ®Google Scholar
• Ravi PR, Aditya N, Kathuria H, et al. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism . Eur J Pharm Biopharm. 2014;87:114–124.
   PubMed Web of Science ®Google Scholar
• Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and “self-microemulsifying” drug delivery systems. Eur J Pharm Sci. 2000;11:S93–S98.
   PubMed Web of Science ®Google Scholar
• Kang BK, Lee JS, Chon SK, et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm. 2004;274:65–73.
   PubMed Web of Science ®Google Scholar
• Karasulu YH, Karabulut B, Goker E, et al. Controlled release of Methotrexate from w/o microemulsion and its in vitro antitumor activity . Drug Deliv. 2007;14:225–233.
   PubMed Web of Science ®Google Scholar
• Yang ZY, Zhang ZF, He XB, et al. Validation of a novel HPLC method for the determination of raloxifene and its pharmacokinetics in rat plasma. Chroma. 2007;65:197–201.
   Web of Science ®Google Scholar
• Tran TH, Poudel BK, Marasini N, et al. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent. Int J Pharm. 2013;443:50–57.
   PubMed Web of Science ®Google Scholar
• Shah NV, Seth AK, Balaraman R, et al. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in-vivo study. J Adv Res. 2016;7:423–434.
   PubMed Web of Science ®Google Scholar
• Jha RK, Tiwari S, Mishra B. Bioadhesive microspheres for bioavailability enhancement of raloxifene hydrochloride: formulation and pharmacokinetics evaluation. AAPS Pharm SciTech. 2011;12:650–657.
   PubMed Web of Science ®Google Scholar
• Burra M, Jukanti R, Janga KY, et al. Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles. Adv Powder Technol. 2013;24:393–402.
   Web of Science ®Google Scholar
• Shah N, Seth AK, Balaraman R. Bioavailability enhancement of poorly soluble raloxifene by designing inclusion complex with β- cyclodextrin. Int J Pharm Pharm Sci. 2015;7:205–211.
   Google Scholar
• Jia L, Zhang D, Li Z, et al. Nanostructured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies. Colloids Surf B Biointerfaces. 2010;80:213–218.
   PubMed Web of Science ®Google Scholar
• Shah NV, Ghelani TK, Saini V, et al. Development and characterization of micro-emulsion based system of aceclofenac. Indo Am J Pharm Res. 2011;2:110–124.
   Google Scholar